Barclays »

Belite Bio shares owned by Barclays

Quarter-by-quarter ownership of Belite Bio (BLTE) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Belite Bio

Tip: Access up to 7 years of quarterly data

All positions including Belite Bio held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Belite Bio by Barclays

Quarter filed Position value Share count Share price at filing
2025-12-31 $668k 4.2k 159.96
2022-09-30 $223k 6.7k 33.48

More positions owned by Barclays

SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Microsoft Corp Opt Put Option (MSFT)
Apple (AAPL)
Ishares Tr Opt Call Option (IWM)
Alphabet Inc Class A cs (GOOGL)
Amazon (AMZN)
Tesla Motors (TSLA)
Facebook Inc cl a (META)
Broadcom (AVGO)
Alphabet Inc Class C cs (GOOG)
Ishares Tr Opt Put Option (HYG)
Advanced Micro Devices (AMD)
JPMORGAN CHASE &amp Opt Put Option (JPM)

View all positions for Barclays

Top funds holding Belite Bio

Darwin Global Management
RA Capital Management
Rtw Investments
Eventide Asset Management
Point72 Asset Management
Deerfield Management Company
Marshall Wace
UBS Group
MPM Oncology Impact Management
Holocene Advisors
Western Standard
Perceptive Advisors
Goldman Sachs Group
Soleus Capital Management
ADAR1 Capital Management

View all funds holding Belite Bio